VVOS Vivos Therapeutics, Inc.
Debt Financing ·
Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed.
We have not published a story on Vivos Therapeutics yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $17.4 million | $15.0 million |
| Research and development | $100,000 | $100,000 |
| Net income (loss) | -$21.2 million | -$11.1 million |
| Cash from operations | -$15.3 million | -$12.7 million |
| Cash and equivalents | $2.0 million | $6.3 million |
Our latest story on this, dated Jun 8, 2026: "Vivos Therapeutics issues convertible note of up to $5,000,000". The story links the filing or release it is based on. Read the story.
Vivos Therapeutics, Inc. trades under the ticker VVOS on NASDAQ.
Vivos Therapeutics, Inc. is listed on NASDAQ.
Our directory records Vivos Therapeutics, Inc. under United States.
aibio.space lists Vivos Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$17.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Vivos Therapeutics, Inc. reported a net loss of $21.2 million for the fiscal year ended Dec 31, 2025, and used $15.3 million of cash in operations, per its annual report to the SEC.
$100,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$1.8 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Vivos Therapeutics, dated Jun 8, 2026: "Vivos Therapeutics issues convertible note of up to $5,000,000". Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed. Source.
Press Follow on this page to add Vivos Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Vivos Therapeutics so far, in Debt Financing.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.03,7.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,3.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio